Mon, January 9, 2012
Sun, January 8, 2012
Sat, January 7, 2012
Fri, January 6, 2012
Thu, January 5, 2012
Wed, January 4, 2012
Tue, January 3, 2012
Mon, January 2, 2012
Sat, December 31, 2011
Fri, December 30, 2011
Thu, December 29, 2011
Wed, December 28, 2011
Tue, December 27, 2011
Mon, December 26, 2011
Fri, December 23, 2011
Thu, December 22, 2011
[ Thu, Dec 22nd 2011 ]: Market Wire
A View from the Top

Regeneron Announces Presentation at the 30th Annual J. P. Morgan Healthcare Conference


  Copy link into your clipboard //health-fitness.news-articles.net/content/2012/ .. 0th-annual-j-p-morgan-healthcare-conference.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

Regeneron Announces Presentation at the 30th Annual J. P. Morgan Healthcare Conference -- TARRYTOWN, N.Y., Jan. 3, 2012 /PRNewswire/ --

Regeneron Announces Presentation at the 30th Annual J. P. Morgan Healthcare Conference

[ ]

TARRYTOWN, N.Y., Jan. 3, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: [ REGN ]) will webcast its presentation at the 30th Annual J. P. Morgan Healthcare Conference on Monday, January 9, 2012.  The presentation is scheduled for 4:00 p.m. Pacific Time (7:00 p.m. Eastern Time).  The session may be accessed through the Company's web site, [ www.regeneron.com ], on the Investor Relations page.  An archived version of the presentation will be available after the live webcast through February 8, 2012. 

Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets two products, ARCALYST® (rilonacept) Injection For Subcutaneous Use and EYLEA™ (aflibercept) Injection.  Regeneron also has completed several Phase 3 studies and is conducting an additional Phase 3 clinical trial for the product candidate ZALTRAP® (aflibercept) Concentrate for Intravenous Infusion.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on the Regeneron web site at [ www.regeneron.com ].

cellpadding="0" cellspacing="0" id="convertedTable" style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; BORDER-COLLAPSE: collapse; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">

Contact Information:                             

 

Michael Aberman, M.D.                        

Peter Dworkin

Investor Relations                                   

Corporate Communications

914.847.7799                                       

914.847.7800

[ michael.aberman@regeneron.com ]       

[ peter.dworkin@regeneron.com ]

 

 

SOURCE Regeneron Pharmaceuticals, Inc.

[ Back to top ]

RELATED LINKS
[ http://www.regeneron.com ]


Publication Contributing Sources